AstraZeneca initiates post-marketing surveillance for Lynparza in South Korea
AstraZeneca is conducting a post-marketing surveillance study to evaluate the safety and effectiveness of Lynparza in real-world settings in South Korea.
Asset / Drug
Drug and asset intelligence for Lynparza with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
PARP Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.